BMEA news

Latest 1 stories · newest Nov 10, 2026

BMEA

Biomea Fusion completes Phase II trial enrollment

Biomea Fusion completed enrollment for the Phase II icovamenib T2D study and dosed the first patient in a new combination trial, projecting cash runway into Q2 2027.

Leadership Nov 10, 2026 sentiment +0.40 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same BMEA feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/BMEA/newsSTART FREE